HK1054033A1 - 4-嘧啶胺衍生物、藥用組合物和相關方法 - Google Patents

4-嘧啶胺衍生物、藥用組合物和相關方法

Info

Publication number
HK1054033A1
HK1054033A1 HK03106375.9A HK03106375A HK1054033A1 HK 1054033 A1 HK1054033 A1 HK 1054033A1 HK 03106375 A HK03106375 A HK 03106375A HK 1054033 A1 HK1054033 A1 HK 1054033A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
related methods
pyrimidinamine derivatives
pyrimidinamine
derivatives
Prior art date
Application number
HK03106375.9A
Other languages
English (en)
Inventor
R Grant Elfrida
K Brown Frank
Allan Zivin Robert
Mcmillan Michael
Zhong Zhong
Scott Malcolm
B Reitz Allen
Morgan Ross Tina
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1054033A1 publication Critical patent/HK1054033A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03106375.9A 2000-08-08 2003-09-08 4-嘧啶胺衍生物、藥用組合物和相關方法 HK1054033A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22379100P 2000-08-08 2000-08-08
PCT/US2001/024659 WO2002012198A2 (en) 2000-08-08 2001-08-06 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
HK1054033A1 true HK1054033A1 (zh) 2003-11-14

Family

ID=22837982

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106375.9A HK1054033A1 (zh) 2000-08-08 2003-09-08 4-嘧啶胺衍生物、藥用組合物和相關方法

Country Status (16)

Country Link
US (3) US20030008883A1 (zh)
EP (1) EP1313713B1 (zh)
JP (1) JP2004505952A (zh)
CN (1) CN1468225A (zh)
AR (1) AR031601A1 (zh)
AT (1) ATE398109T1 (zh)
AU (1) AU2001281120A1 (zh)
BR (1) BR0113165A (zh)
CA (1) CA2419030A1 (zh)
DE (1) DE60134414D1 (zh)
HK (1) HK1054033A1 (zh)
IL (1) IL154240A0 (zh)
MX (1) MXPA03001226A (zh)
NZ (1) NZ524100A (zh)
WO (1) WO2002012198A2 (zh)
ZA (1) ZA200301868B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486376A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
CA2531490A1 (en) * 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
AU2004259346A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
EP1689740A1 (en) 2003-11-24 2006-08-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
CA2556239A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
ATE434614T1 (de) 2004-06-28 2009-07-15 Bayer Schering Pharma Ag 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
US7314933B2 (en) 2004-10-22 2008-01-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2011118812A1 (ja) * 2010-03-26 2011-09-29 国立大学法人北海道大学 神経変性疾患治療薬
ES2661717T3 (es) * 2012-08-23 2018-04-03 Virostatics Srl Derivados de aminopirimidina 4,6-disustituidos novedosos
SG10201908558WA (en) * 2013-12-11 2019-10-30 Biogen Ma Inc Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology
SG11202003441VA (en) * 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068271A (en) * 1988-09-21 1991-11-26 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines compositions
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
AU751573C (en) * 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
EP1045693B1 (en) * 1998-10-16 2004-06-30 Daiichi Suntory Pharma Co., Ltd. Aminophenoxyacetic acid derivatives as neuroprotectants
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体

Also Published As

Publication number Publication date
AR031601A1 (es) 2003-09-24
US20030008883A1 (en) 2003-01-09
WO2002012198A2 (en) 2002-02-14
US20030212079A1 (en) 2003-11-13
IL154240A0 (en) 2003-07-31
CA2419030A1 (en) 2002-02-14
MXPA03001226A (es) 2004-09-10
DE60134414D1 (de) 2008-07-24
NZ524100A (en) 2005-01-28
EP1313713A2 (en) 2003-05-28
JP2004505952A (ja) 2004-02-26
ZA200301868B (en) 2004-06-25
CN1468225A (zh) 2004-01-14
BR0113165A (pt) 2003-07-15
EP1313713B1 (en) 2008-06-11
WO2002012198A3 (en) 2002-06-06
US20040006094A1 (en) 2004-01-08
AU2001281120A1 (en) 2002-02-18
ATE398109T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
HUP0301146A3 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
DZ3313A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DZ3311A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
IL152448A0 (en) 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
HUP0302997A3 (en) Phenylalanine derivatives with alpha4-integrin effect, pharmaceutical compositions containing them and their use
IL151952A0 (en) Aminopyridine derivatives and pharmaceutical compositions containing the same
HUP0303069A3 (en) Imidazole derivatives, pharmaceutical compositions containing them and their use
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
IL154096A0 (en) Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
IL153487A0 (en) Pharmaceutical compositions and methods for use
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
IL153897A0 (en) Pharmaceutical compositions and methods for use
IL154986A0 (en) Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
HK1052168A1 (en) N-deacetylthiocolchincine derivatives and pharmaceutical compositions containing them.